RxDoctor Payments DataLook up a doctor →

Kishan Maramraj, MD

Family Medicine · Salisbury, NCNPI 1144266826

Payments from drug & device makers

$2,581,815in general payments, 2019–2025

Across 359 payments — averaging $7191.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$961K
  • GSK$461K
  • Genentech, Inc.$316K
  • Hoffmann-la Roche Limited$292K
  • Regeneron$149K
  • Novartis$146K
  • plus $256K from 17 others

What the payments were for

  • Food & beverage$659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,581,815 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$238,888
Medicare patients
498
Services billed
9,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide178$226,394
EliquisApixaban136$149,511
MounjaroTirzepatide89$115,644
JardianceEmpagliflozin55$61,857
Tresiba Flextouch U-200Insulin Degludec27$51,106
FarxigaDapagliflozin Propanediol39$47,215
RybelsusSemaglutide16$38,867
JanuviaSitagliptin Phosphate32$32,740
XareltoRivaroxaban35$32,580
TrulicityDulaglutide14$31,208
LinzessLinaclotide17$17,246
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$16,869
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$16,669
SularNisoldipine11$13,064
Breo ElliptaFluticasone/Vilanterol27$12,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$69$265,261194 claims
PfizerEliquis$34,441$149,511136 claims
Lilly USA, LLCMounjaro, Trulicity$28$146,852103 claims
AstraZenecaFarxiga, Symbicort$17,610$54,10653 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$461,180$35,58078 claims
AbbVieLinzess, Synthroid$97$19,11746 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Salisbury

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →